Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (2691)	9/15/1999 2:06:00 AM
From: synchro	Read Replies (2) \| Respond to of 4676

Critical mass would be reached if they get a cancer drug convincingly approved. That would be a tremendous validation of antisense. The instant the cancer drug is approved, the Street would start to discount not just the potential profit from that one cancer drug, but the potential profit from the whole antisense platform. THAT's when a fortune can be made from the stock. So assuming they have a successful Phase III trial, watch for the initial huge pop the instant FDA approves their first cancer drug. That is a sign to scale up, and don't sell your holdings to take some quick profits. And if you didn't invest much to before the pop, don't think you have missed the "ground floor"--the subsequent multi-week surge would make the initial pop look insignificant. If you want to see what a change in perceptation of a technology from skepticism to wholesale embrace can do to a stock's price, just watch what happened to Qualcomm. The same will happen to Isis' antisense -- assuming the technology eventually proves credible. Right now I think some healthy skepticism is warranted. I just can't get over the fact that the other biotechs are willing to sell their antisense portfolio to Isis. That's a pretty significant 'tell' from industry insiders, isn't it?